Bexsero

Gorringe, Andrew; Pajón, Rolando

doi:10.4161/hv.18500

Cited by 108 publications

(51 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, immunization using pathogen-derived OMVs results in the stimulation of a strong immune response and protection in murine models [21–23]. In the most notable case, Neisseria meningitidis- derived OMVs have been used in the formulation of the vaccine Bexsero (Novartis), which is approved for use in Europe [24]. Unfortunately, widespread development of OMVs in the context of vaccines is hindered by several obstacles: scale of production, versatility, and toxicity.…”

Section: Introductionmentioning

confidence: 99%

Microbial biosynthesis of designer outer membrane vesicles

Baker

Chen

Rosenthal

et al. 2014

Current Opinion in Biotechnology

View full text Add to dashboard Cite

Outer membrane vesicles (OMVs) are nanoscale proteoliposomes that are ubiquitously secreted by Gram-negative bacteria. Interest in these bioparticles has escalated over the years, leading to discoveries regarding their composition, production, and vaccine potential. Given that many steps in vesicle biogenesis are ‘engineerable,’ it is now possible to tailor OMVs for specific applications. Such tailoring involves modifying the OMV-producing bacterium through protein, pathway, or genome engineering in a manner that specifically alters the final OMV product. For example, targeted deletion or upregulation of genes associated with the cell envelope can modulate vesicle production or remodel the composition of vesicle components such as lipopolysaccharide. Likewise, bacteria can be reprogrammed to incorporate heterologously expressed proteins into either the membrane or lumenal compartment of OMVs. We anticipate that further research in the field of OMV engineering will enable continued design and biosynthesis of specialized vesicles for numerous biotechnological purposes ranging from the delivery of vaccines to the deconstruction of cellulosic substrates.

show abstract

Section: Introductionmentioning

confidence: 99%

Microbial biosynthesis of designer outer membrane vesicles

Baker

Chen

Rosenthal

et al. 2014

Current Opinion in Biotechnology

View full text Add to dashboard Cite

show abstract

“…OMV-based vaccines have been used on a large scale for the control of clonal outbreaks of meningococcal disease (5)(6)(7). Additionally, a recombinant protein-based vaccine containing OMV is currently in advanced clinical trials and was recently licensed in Europe (8). OMV-based vaccines are immunogenic; however, protection is restricted to the variants of the antigens in the vaccine, with the surface protein PorA being immunodominant and a major component of the OMVs.…”

mentioning

confidence: 99%

Neisseria meningitidis Native Outer Membrane Vesicles Containing Different Lipopolysaccharide Glycoforms as Adjuvants for Meningococcal and Nonmeningococcal Antigens

Nagaputra

Rollier

Sadarangani

et al. 2013

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

“…3,29 Their use provided good results in terms of containment of outbreaks in Cuba, New Zealand, Norway, and France (Normandy). 30,31 In January 2013, the European Commission granted marketing authorization of the vaccine against the MenB (4CMenB), containing three recombinant proteins and OMV derived from NZ98/254 MenB strain. This vaccine has been produced using the innovative technique of reverse vaccinology, which led to the identification of new MenB antigens able to induce a bactericidal response.…”

Section: Vaccinesmentioning

confidence: 99%

“…The OMVs of the epidemic strain of the New Zealand NZ98/254, able to induce a robust antibody response, were also added. 31,32 In detail, fHbp is a surface lipoprotein that binds to human factor H and by blocking this inhibitor of the alternative complement pathway favors bacterial survival in human blood. Nad A is a surface protein that mediates the adhesion and the entrance of the pathogen in the nasopharingeal epithelial cells; five variants of this adhesin have been identified.…”

Section: Vaccinesmentioning

confidence: 99%

Meningococcal B vaccination: real-world experience and future perspectives

Kuhdari

Stefanati

Lupi

et al. 2016

Pathogens and Global Health

View full text Add to dashboard Cite

Invasive meningococcal disease (IMD) represents a severe risk for health. It can be considered the most dangerous vaccine-preventable disease due to the high probability of related permanent sequelae and death. The introduction in many countries of the conjugate vaccines against A, C, W135, and Y meningococcal serogroups influenced significantly the impact of the disease. Recently, the difficulties in obtaining an effective vaccine against meningococcal serogroup B (MenB) have been get over through the reverse vaccinology, enabling the recognition of some antigens providing a response against most of circulating MenB strains worldwide. The new 4cMenB vaccine is recommended in Europe, Canada, Australia, the USA, and some Latin American countries. Even if sound data on efficacy and safety profile are available, the results in terms of effectiveness are still limited. The management of the MenB outbreaks in two US universities demonstrated the ability to quickly achieve high vaccination coverage rates and no new cases among immunized subjects were assessed. It is desirable that the opportunity to complete preventive intervention against IMD offered by the new 4cMenB vaccine should be recognized and that this vaccine is included in the vaccination schedule to complete the panel of immunization against Neisseria meningitidis.

show abstract

Bexsero

Cited by 108 publications

References 62 publications

Microbial biosynthesis of designer outer membrane vesicles

Microbial biosynthesis of designer outer membrane vesicles

Neisseria meningitidis Native Outer Membrane Vesicles Containing Different Lipopolysaccharide Glycoforms as Adjuvants for Meningococcal and Nonmeningococcal Antigens

Meningococcal B vaccination: real-world experience and future perspectives

Contact Info

Product

Resources

About